Tyrosine News and Research

RSS

Researchers discover origin of resistance to lung cancer

For treating cancer, drugs based on molecules known as tyrosine kinase inhibitors are sometimes used. One such tyrosine kinase inhibitor, called osimertinib, has been used to treat EGFR-mutated lung cancer with a certain degree of efficacy.

25 Feb 2019

Study: Cancer stem-like cells are maintained by MTHFD2 mitochondrial metabolic enzyme

An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer.

22 Feb 2019

Drug increases melanin production in some people with albinism

A small pilot clinical study at the National Eye Institute suggests that the drug nitisinone increases melanin production in some people with oculocutaneous albinism type 1B, a rare genetic disease that causes pale skin and hair and poor vision.

21 Feb 2019

First molecular test predicts treatment response for kidney cancer

Immunotherapy drugs such as PD-L1 checkpoint inhibitors represent the front-line treatment for kidney cancer. But immunotherapy is expensive, benefits only a subset of patients and is futile in the majority of patients.

19 Feb 2019

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad's Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry's first digital PCR products to receive U.S. Food and Drug Administration clearance.

15 Feb 2019

New drug compounds show promise in treating acute myeloid leukemia

Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society.

29 Jan 2019

Study shows how gut bacteria affect the treatment of Parkinson's disease

Patients with Parkinson's disease are treated with levodopa, which is converted into dopamine, a neurotransmitter in the brain. In a study published on 18 January in the journal Nature Communications, scientists from the University of Groningen show that gut bacteria can metabolize levodopa into dopamine.

18 Jan 2019

Drug combination has added benefit for patients with melanoma

The German Institute for Quality and Efficiency in Health Care investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with the appropriate comparator therapies for patients with melanoma.

9 Jan 2019

Egg metabolites in blood linked to reduced risk of type 2 diabetes

Consumption of one egg every day seems to associate with a blood metabolite profile that is related to a lower risk of type 2 diabetes, a new study conducted in the University of Eastern Finland shows.

3 Jan 2019

Using Assay Kits and Dyes to Advance Cell Biology Research

In this interview, Richard Delle Bovi highlights live cell ability of the CELLESTIAL® analysis kit from Enzo Life Sciences and its applications in cell biology.

From Enzo Life Sciences, Inc. 2 Jan 2019

Research reviews role of protein tyrosine phosphatase in molecular biology

As the proteomics technology develops and human genomic analysis becomes easier to execute, molecules involved in the regulation of biochemical signaling pathways have become interesting subjects for researchers.

28 Dec 2018

New study describes various gene therapy strategies for treating Parkinson's disease

Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor deficits majorly caused by the loss of dopaminergic cells in the Substantia Nigra pars compacta as well as the destruction of nigrostriatal pathway.

28 Dec 2018

New project aims to understand why and how metabolic disorders develop in patients

The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.

13 Dec 2018

Researchers develop biosensors to detect and measure metastatic potential of cancer cells

The spread of invasive cancer cells from a tumor's original site to distant parts of the body is known as metastasis. It is the leading cause of death in people with cancer. In a paper published online in iScience, University of California San Diego School of Medicine researchers reported engineering sensors that can detect and measure the metastatic potential of single cancer cells.

6 Dec 2018

FDA grants accelerated approval to oncology drug for treatment of key genetic driver of cancer

The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

27 Nov 2018

Researchers shed light on molecular mechanisms of heart valvular disease

About three per cent of the world's population is affected by valvular heart diseases. It is also the most common cause of heart surgery, as no drug-based treatment is available.

20 Nov 2018

Study identifies novel missense mutation affecting YARS causes multisystem disease

Researchers have identified a novel missense mutation in tyrosyl-tRNA synthetase (YARS c.499C>A, p.Pro167Thr) that causes a severe recessive disorder in affected individuals.

7 Nov 2018

New nuclear medicine tracer could improve diagnosis, treatment of non-small cell lung cancer

Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non-small cell lung cancer.

7 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Scientists find ways to block nitration of amino acids to improve cancer immunotherapy

Immunotherapy -- harnessing T-cells to attack cancer cells in the body -- has given hope to patients who endure round after round of treatment, including chemotherapy, to little effect. For all of its promise, however, immunotherapy still benefits only a minority of patients -- a reality driving research in the field for ways to improve the relatively new approach.

30 Oct 2018